On May 21, 2012, the American Urological Association (AUA) issued the first guidelines specific to the diagnosis and treatment of overactive bladder (OAB) in the U.S. Astellas supports these new treatment guidelines, which could serve as a decision-making tool for health care professionals. Astellas applauds the AUA for taking this valuable step forward to ensure patients receive the highest standard of care available and for recognizing the value that pharmaceutical treatments provide to patients. Treatment guidelines should be continually reviewed and updated to reflect scientific advancements and all available treatment options—particularly those that address an unmet need.

Affecting more than 42 million Americans, OAB is a serious condition and symptoms can be problematic, unpredictable, have damaging effects on an individual’s daily routine and lead to more serious health problems. Astellas is committed to working with the AUA and the professional community to ensure all options are considered as part of a standardized treatment approach to OAB the addresses the unmet need in this category.

Astellas is committed to becoming a global category leader in urology and providing solutions for physicians and patients through the discovery of new treatments for OAB and other urologic conditions, including benign prostatic hyperplasia, pelvic pain and urologic cancers.